钆塞酸增强MRI作为肝细胞癌管理中的诊断工具:2020年亚太多学科专家会议报告
本文为2020年9月28日首次召开的亚太地区肝病多学科专家在线顾问会议及其后续讨论的成果,综述了钆塞酸的使用技术考量、其在肝细胞癌(HCC)患者管理中的当前作用、在HCC影像诊断共识指南中的相关性,并审视了近期关于钆塞酸从诊断到治疗决策及随访全程对临床结局影响的证据,最后基于对该对比剂临床效用不断演变的理解,概述了钆塞酸MRI未来可能的作用。
要点
- 钆塞酸MRI广泛用于肝脏成像,需同时理解其优势与局限性。
- 综述涵盖钆塞酸技术考量、在HCC管理中的作用及与共识指南的相关性。
- 近期证据评估钆塞酸对从诊断到治疗决策及随访全程临床结局的影响。
核心结论
- 基于对钆塞酸临床效用不断演变的理解,本文概述了钆塞酸MRI在HCC风险人群或HCC患者管理中未来可能的作用。
研究设计与样本
- 本文为2020年9月28日首次召开的亚太地区肝病多学科专家在线顾问会议及其后续讨论的成果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Gadoxetate magnetic resonance imaging (MRI) is widely used in clinical practice for liver imaging. For optimal use, we must understand both its advantages and limitations. This article is the outcome of an online advisory board meeting and subsequent discussions by a multidisciplinary group of experts on liver diseases across the Asia-Pacific region, first held on September 28, 2020. Here, we review the technical considerations for the use of gadoxetate, its current role in the management of patients with hepatocellular carcinoma (HCC), and its relevance in consensus guidelines for HCC imaging diagnosis. In the latter part of this review, we examine recent evidence evaluating the impact of gadoxetate on clinical outcomes on a continuum from diagnosis to treatment decision-making and follow-up. In conclusion, we outline the potential future roles of gadoxetate MRI based on an evolving understanding of the clinical utility of this contrast agent in the management of patients at risk of, or with, HCC.
引用
- Tan CH, Chou SC, Inmutto N, et al. Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting. Korean J Radiol. 2022. PMID: 35555884. doi:10.3348/kjr.2021.0593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。